SO-29: Clinical characteristics, efficacy, and safety in patients receiving second- or third-line encorafenib plus cetuximab (E+C) vs control for metastatic colorectal cancer (mCRC): BEACON CRC post hoc analysis

Abstract Presenter(s)

• 

  Josep Tabernero, MD

  Vall d’Hebron University Hospital
  Barcelona, Spain